Olumiant (Baricitinib) Patent Expiration, LOE Window & CMS Spending

Olumiant (Baricitinib) by Eli Lilly: FDA Orange Book core substance LOE 2032-05-31 (last listed 2032-11-30), 1 AB generics, $68.1M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEli Lilly
FDA Application & PathwayN207924 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2032-05-31
Last Listed Patent or Exclusivity Date2032-11-30
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$68.1M
2024 Medicare Part D Spend$35.4M
2024 Medicaid Spend$32.7M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.